Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction.
Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Zangari B, et al. Among authors: eppolito c. Cancer Immunol Immunother. 2022 Dec;71(12):2881-2898. doi: 10.1007/s00262-022-03197-2. Epub 2022 Apr 23. Cancer Immunol Immunother. 2022. PMID: 35460379 Free PMC article.
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer.
Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K. Muthuswamy R, et al. Among authors: eppolito c. J Immunother Cancer. 2021 Oct;9(10):e003329. doi: 10.1136/jitc-2021-003329. J Immunother Cancer. 2021. PMID: 34607898 Free PMC article.
Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8+ T‑cells from GzmB mediated self‑destruction.
Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Zangari B, et al. Among authors: eppolito c. Cancer Immunol Immunother. 2022 Dec;71(12):2899. doi: 10.1007/s00262-022-03233-1. Cancer Immunol Immunother. 2022. PMID: 35666273 Free PMC article. No abstract available.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. Matsuzaki J, et al. Among authors: eppolito c. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12. Proc Natl Acad Sci U S A. 2010. PMID: 20385810 Free PMC article.
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR, Huang RY, Battaglia S, Eppolito C, Miliotto A, Stephenson KB, Lugade AA, Webster G, Lichty BD, Seshadri M, Kozbor D, Odunsi K. McGray AJR, et al. Among authors: eppolito c. J Immunother Cancer. 2019 Jul 17;7(1):189. doi: 10.1186/s40425-019-0641-x. J Immunother Cancer. 2019. PMID: 31315674 Free PMC article.
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
McGray AJR, Eppolito C, Miliotto A, Singel KL, Stephenson K, Lugade A, Segal BH, Keler T, Webster G, Lichty B, Kozbor D, Odunsi K. McGray AJR, et al. Among authors: eppolito c. Cancer Immunol Immunother. 2021 Dec;70(12):3451-3460. doi: 10.1007/s00262-021-02936-1. Epub 2021 Apr 20. Cancer Immunol Immunother. 2021. PMID: 33880648 Free PMC article.
26 results